Sooam's bovine research focuses on creating transgenic cows that can produce therapeutic proteins in their milk. Currently, the number of proteins being produced by the biomedical industry is growing rapidly and as the demand for these proteins increases in the future, we must find a way to supply it. A cow produces 10,000 L (~ 2,600 gallons) of milk every year, which makes them an attractive option for mass production of desired proteins. In other words, a transgenic cow can potentially be used as a "bioreactor" for producing useful proteins. At Sooam, we are focusing on creating transgenic cows that can produce interferon and human erythropoietin in their milk.

Interferon is a protein that triggers the immune system to defend the body against pathogens, and erythropoietin is a hormone that controls red blood cell production. Those who suffer from the lack of interferon or erythropoietin can greatly benefit from transgenic cows that can produce these important proteins.

In May, 2011 Sooam signed an agreement with the Rural Development Administration of Korea for a national R&D project titled "Delivery of Transgenic Cow for Production of Interferon."